BriaCell Therapeutics Corp. (BCTX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 West Vancouver, BC, 캐나다. 현재 CEO는 William V. Williams.
BCTX 을(를) 보유 IPO 날짜 2012-03-14, 16 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $8.7M.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
